mirvetuximab soravtansine
2 stories
-
healthNHS Greenlights Revolutionary Ovarian Cancer Drug After Two-Decade Hiatus
NHS approves AbbVie's targeted therapy mirvetuximab soravtansine for platinum resistant ovarian cancer, extending survival and marking the first new treatment in 20 years.
-
healthNHS Approves New ‘Trojan Horse’ Drug for Ovarian Cancer
NHS approves mirvetuximab soravtansine, a targeted therapy extending survival for hard-to-treat ovarian cancer patients.